Publication | Closed Access

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

Bone DiseaseBone HealthOrthopaedicsExtension StudyPlacebo-controlled StudySurgeryMedicineOsteoporosisOrthopaedic Surgery